Innoviva, Inc. splits its revenue into 6 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Royalty at $236.5 million, 57% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
438
|
411
|
359
|
310
|
331
|
392
|
337
|
261
|
261
|
217
|
134
|
| Royalty |
221
-9.4%
share 50.4%
|
236
-2.2%
share 57.5%
|
242
+1.2%
share 67.4%
|
239
-23.4%
share 76.9%
|
312
-20.5%
share 94.1%
|
392
+19.9%
share 100.0%
|
327
+25.2%
share 97.0%
|
261
+0.0%
share 100.0%
|
261
+21.9%
share 100.0%
|
214
share 98.6%
|
—
|
| Product |
202
+42.0%
share 46.0%
|
172
+76.6%
share 41.8%
|
97
+60.8%
share 27.2%
|
61
share 19.5%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Xerava |
20
-9.6%
share 4.6%
|
24
+10.0%
share 5.7%
|
21
+23.5%
share 6.0%
|
17
+216.1%
share 5.6%
|
5
share 1.7%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Collaborative Arrangements |
—
|
—
|
—
|
—
|
—
|
—
|
10
share 3.0%
|
—
|
—
|
3
share 1.4%
|
—
|
| License And Other Revenue |
16
+546.0%
share 3.6%
|
3
-86.0%
share 0.7%
|
19
+77.1%
share 5.4%
|
11
share 3.5%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| ZEVTERA |
2
share 0.4%
|
1
share 0.1%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INVA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Burlingame, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1080014
- Former names
- THERAVANCE INC (until Dec 7, 2015); ADVANCED MEDICINE INC (until Aug 2, 2000)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.